ABBV Earnings & Financial Statements
AbbVie Inc.
$283.48
+$9.12(+3.32%)
70
Overall
60
Value
100
Tech
50
Quality
Market Cap
$500.94B
Volume
5.59M
52W Range
$190.75 - $277.60
Target Price
$281.70
ABBV earnings and financial statements: AbbVie Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ABBV Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Cost of revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B |
| Operating income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B |
| EBITDA | $17.39B | $14.24B | $16.59B | $24.18B | $23.93B |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| EPS (diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B |
| Total liabilities | $137.19B | $131.80B | $124.31B | $121.52B | $131.09B |
| Shareholders’ equity | -$3.27B | $3.33B | $10.36B | $17.25B | $15.41B |
| Cash and equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B |
| Long-term debt | $58.94B | $60.34B | $52.19B | $59.13B | $64.19B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B |
| Capital expenditure | -$1.21B | -$974.00M | -$777.00M | -$695.00M | -$787.00M |
| Free cash flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B |
| Dividends paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABBV | $283.48 | +3.3% | 5.59M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |